Stuart Therapeutics, Inc.
PrivateLast Round
Series A
Mar 19, 2021
Total Funding Raised
$11M
Company Overview
Stuart Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in Stuart, Florida. Its latest recorded funding round was a Series A round in March 2021.
Stuart Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops a synthesized peptide therapeutic platform intended to repair disease-damaged helical collagen in the eye.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B2C
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stuart Therapeutics, Inc. Comparables
Compare Stuart Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TearSolutions | 87% | |
| Selagine, Inc. | 81% | |
| Aldeyra Therapeutics | 81% |
For institutional investors. Book with your work email.
Stuart Therapeutics, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Stuart Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioBrit | Series A |
| Wisconsin Alumni Research Foundation | Series A |
| InFocus Capital Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 46% MoM.
- May 2, 2025
Monthly visitors increased 32% MoM, reaching 1.3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
Stuart Therapeutics, Inc. presents at the Citizens Private Ophthalmology Summit on Sep 17th '26, with President and CEO Eric Schlumpf participating in a fireside chat.
- hiresAug 26, 2026
Stuart Therapeutics, Inc. appoints Dave LeCause as senior commercial advisor in Florida on Aug 26th '26, with LeCause leading the company's commercial strategy as it advances ST-100 for dry eye disease.
- hiresAug 19, 2026
On Aug 18th '26, Stuart Therapeutics, Inc. appoints David Jakeman as chief financial officer in Florida, where he leads its finance and accounting operations as it advances ST-100 for dry eye disease through its pending Phase 3b trial and prepares for commercialization.
For institutional investors. Book with your work email.
Stuart Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Stuart Therapeutics, Inc.'s valuation, stock price, and market status.
Is Stuart Therapeutics, Inc. a public or private company?
Stuart Therapeutics, Inc. is a private company.
What is the current stock price of Stuart Therapeutics, Inc.?
Stuart Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Stuart Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stuart Therapeutics, Inc. worth (valuation)?
Valuation information for Stuart Therapeutics, Inc. is not publicly available.
Can I buy Stuart Therapeutics, Inc. stock?
Stuart Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stuart Therapeutics, Inc.'s last funding round?
Stuart Therapeutics, Inc.'s most recent funding round was Series A on March 19, 2021.
Who are the main investors in Stuart Therapeutics, Inc.?
Key investors in Stuart Therapeutics, Inc. include InFocus Capital Partners.
Will Stuart Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Stuart Therapeutics, Inc..
How can I track Stuart Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Stuart Therapeutics, Inc.'s shares on secondary markets.